Get started
Author

Cornelia Wurzenberger

Observed name: Wurzenberger, Cornelia
ORCID: 0009-0007-5802-2092
Observed ORCID: 0009-0007-5802-2092
OpenAlex ID: A5000551241
Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity
2008 · Carole Bourquin, David Anz, et al. · The Journal of Immunology · 152
Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2011 · Carole Bourquin, Christian Hotz, et al. · Cancer Research · 85
Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
2015 · David Anz, Moritz Rapp, et al. · Cancer Research · 76
PDF
Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response
2006 · Carole Bourquin, Laura Schmidt, et al. · Blood · 64
Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7
2009 · Carole Bourquin, Laura Schmidt, et al. · The Journal of Immunology · 42
The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo
2012 · Jan Endell, Rainer Boxhammer, et al. · Blood · 37
Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response
2010 · Carole Bourquin, Cornelia Wurzenberger, et al. · Journal of Immunotherapy · 31
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment
2025 · Vanessa Neiens, Eva-Maria Hansbauer, et al. · Nature Communications · 21
PDF
Efficient Eradication of Subcutaneous but Not of Autochthonous Gastric Tumors by Adoptive T Cell Transfer in an SV40 T Antigen Mouse Model
2010 · Carole Bourquin, Philip von der Borch, et al. · The Journal of Immunology · 21
PDF
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2024 · Sarina Piha-Paul, Shane A. Olwill, et al. · Clinical Cancer Research · 18
PDF
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
2008 · Cornelia Wurzenberger, Viktor H. Koelzer, et al. · Cancer Immunology Immunotherapy · 17
PDF
Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction
2024 · Katharina Heinzelmann, Athanasios Fysikopoulos, et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 5
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
2021 · Vanessa Welk, Marina Pavlidou, et al. · European Respiratory Journal · 3
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Dendritic cell vaccines in tumor immunotherapy: Immune activation strategies with ligands for the Toll-like receptors 7 and 9
2008 · Cornelia Wurzenberger · 1
Supplementary Figure S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Data from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Table S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Table S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Table S5 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Table S4 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Figure S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Supplementary Table S3 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
2025 · Sarina Piha-Paul, Shane A. Olwill, et al.
Data from Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
2023 · David Anz, Moritz Rapp, et al.
Supplementary Figure 3 from Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
2023 · David Anz, Moritz Rapp, et al.
Supplementary Figure 4 from Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression
2023 · David Anz, Moritz Rapp, et al.
Works count: 43
Citation count: 573
H-index: 11
I10-index: 11
Year
Topic
Type